Wasatch Advisors LP Invests $40.53 Million in Ralliant Corporation $RAL

Wasatch Advisors LP bought a new stake in shares of Ralliant Corporation (NYSE:RAL) during the 2nd quarter, according to its most recent filing with the SEC. The fund bought 550,399 shares of the company’s stock, valued at approximately $40,526,000. Wasatch Advisors LP owned approximately 0.49% of Ralliant as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Danske Bank A S acquired a new stake in Ralliant in the 4th quarter valued at $25,000. Allworth Financial LP grew its holdings in shares of Ralliant by 134.4% during the fourth quarter. Allworth Financial LP now owns 511 shares of the company’s stock worth $26,000 after purchasing an additional 293 shares during the last quarter. V Square Quantitative Management LLC bought a new stake in shares of Ralliant during the fourth quarter worth $26,000. Palisade Asset Management LLC acquired a new stake in shares of Ralliant in the third quarter valued at $26,000. Finally, Versant Capital Management Inc increased its stake in shares of Ralliant by 230.1% in the second quarter. Versant Capital Management Inc now owns 604 shares of the company’s stock valued at $44,000 after buying an additional 421 shares in the last quarter.

Ralliant Trading Up 3.2%

RAL stock opened at $71.60 on Wednesday. The company has a quick ratio of 1.00, a current ratio of 1.52 and a debt-to-equity ratio of 0.75. Ralliant Corporation has a twelve month low of $37.27 and a twelve month high of $75.41. The company has a market cap of $7.92 billion, a P/E ratio of -6.60, a PEG ratio of 2.58 and a beta of 1.61. The business has a fifty day moving average of $67.98 and a 200-day moving average of $55.06.

Ralliant (NYSE:RAL) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.63 by $0.05. The business had revenue of $567.80 million for the quarter. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. As a group, equities research analysts expect that Ralliant Corporation will post 2.87 EPS for the current year.

Ralliant Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 23rd. Stockholders of record on Tuesday, September 8th will be paid a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 8th. Ralliant’s dividend payout ratio (DPR) is -1.84%.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on RAL. Royal Bank Of Canada upped their price target on shares of Ralliant from $71.00 to $73.00 and gave the stock a “sector perform” rating in a research report on Friday, July 31st. Evercore started coverage on shares of Ralliant in a research report on Tuesday, June 9th. They issued an “outperform” rating and a $80.00 price objective for the company. Zacks Research raised shares of Ralliant from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, June 30th. Weiss Ratings reiterated a “sell (d)” rating on shares of Ralliant in a research report on Friday, July 31st. Finally, Morgan Stanley increased their price target on shares of Ralliant from $68.00 to $85.00 and gave the company an “overweight” rating in a research note on Tuesday, June 23rd. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $75.70.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.